Skip to main content
. 2014 May;88(10):5242–5255. doi: 10.1128/JVI.03819-13

FIG 7.

FIG 7

(A) Tumor rejection in C57BL/6 mice vaccinated with MVATG9931 and NAB2-Lipofectin (12 mice per group). (B) NAB2-Lipofectin increases the efficacy of MVATG9931 in four independent experiments. The effect was statistically significant, according to hazard ratio analysis.